These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24305618)

  • 1. Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.
    Mostaghel EA; Plymate SR; Montgomery B
    Clin Cancer Res; 2014 Feb; 20(4):791-8. PubMed ID: 24305618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of androgen receptor splice variants, their clinical relevance and treatment options.
    Wach S; Taubert H; Cronauer M
    World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
    Culig Z; Santer FR
    Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway.
    Mellado B; Codony J; Ribal MJ; Visa L; Gascón P
    Clin Transl Oncol; 2009 Jan; 11(1):5-10. PubMed ID: 19155198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular determinants of resistance to antiandrogen therapy.
    Chen CD; Welsbie DS; Tran C; Baek SH; Chen R; Vessella R; Rosenfeld MG; Sawyers CL
    Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming castration resistance in prostate cancer.
    Tsao CK; Small AC; Galsky MD; Oh WK
    Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New hormonal therapies for castration-resistant prostate cancer.
    Mostaghel EA; Plymate S
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):625-42, x. PubMed ID: 21889725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel drugs targeting the androgen receptor pathway in prostate cancer.
    Mateo J; Smith A; Ong M; de Bono JS
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular alterations during progression of prostate cancer to androgen independence.
    Saraon P; Jarvi K; Diamandis EP
    Clin Chem; 2011 Oct; 57(10):1366-75. PubMed ID: 21956922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
    Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
    J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
    Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathogenesis and progression of prostate cancer.
    Schrecengost R; Knudsen KE
    Semin Oncol; 2013 Jun; 40(3):244-58. PubMed ID: 23806491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Splicing variant of androgen receptors (AR-V7): New paradigms].
    Penel N
    Bull Cancer; 2016 Sep; 103(9):711-3. PubMed ID: 27591905
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and biological characterization of a novel series of androgen receptor modulators.
    Zhou C; Wu G; Feng Y; Li Q; Su H; Mais DE; Zhu Y; Li N; Deng Y; Yang D; Wang MW
    Br J Pharmacol; 2008 May; 154(2):440-50. PubMed ID: 18414397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
    D'Antonio JM; Ma C; Monzon FA; Pflug BR
    Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options in hormone-refractory metastatic prostate carcinoma.
    Fusi A; Procopio G; Della Torre S; Ricotta R; Bianchini G; Salvioni R; Ferrari L; Martinetti A; Savelli G; Villa S; Bajetta E
    Tumori; 2004; 90(6):535-46. PubMed ID: 15762353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.
    Silberstein JL; Taylor MN; Antonarakis ES
    Curr Urol Rep; 2016 Apr; 17(4):29. PubMed ID: 26902623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.